|Articles|April 10, 2018
Shanghai HEP Pharma Signs Agreement with OmniComm Systems
Advertisement
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
2
ACT Brief: Patient Preferences in Remote Trials, Sanofi’s Neurology and Immunology Deals, and AI-Driven Biomarkers in Oncology
3
FDA Approves GSK’s Exdensur for Severe Asthma Based on SWIFT Phase III Data
4
Unlocking Unstructured Health Data: Scaling eSource-Enabled Clinical Trials
5